Abstract |
Analysis of the efficacy and tolerability of gemfibrozil ( Gevilon-Parke Davis) was performed including 29 patients aged 19-69 years with primary hyperlipoproteinemia (HLP) type IIb-16 persons, IV-13 persons. All patients got dietary recommendations and received gemfibrozil 450-900 mg/day for 3 months. In both types of HLP a significant reduction of serum cholesterol (TCh)--15.5% triglycerides (TG)--32.1% VLDL-Ch--34.9% and VLDL-TG concentration--36.6% was observed as well as an increase of HDL3 fraction-16.3%. The greatest reduction of serum TCh concentration and VLDL-Ch were observed in type IIb, while that of TG and VLDL-TG in type IV HLP. The best therapeutic effect was obtained during the first month of treatment. The percent of TCh, TG, VLDL-Ch, VLDL-TG reduction correlated with their initial level. Tolerability of gemfibrozil was very good. Only in 2 patients transient abdominal pain was observed.
|
Authors | M Polakowska, G Broda, S Rywik, W Piotrowski, M Bednarska, A Kuźmińska, A Pytlak, E Chotkowska |
Journal | Polskie Archiwum Medycyny Wewnetrznej
(Pol Arch Med Wewn)
Vol. 91
Issue 1
Pg. 9-18
(Jan 1994)
Poland |
Vernacular Title | Ocena skuteczności gemfibrozilu w leczeniu hiperlipidemii typu IIb i IV. |
PMID | 8190659
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Cholesterol, VLDL
- Triglycerides
- Cholesterol
- Gemfibrozil
|
Topics |
- Adolescent
- Adult
- Aged
- Cholesterol
(blood)
- Cholesterol, VLDL
(blood)
- Female
- Gemfibrozil
(therapeutic use)
- Humans
- Hyperlipoproteinemia Type II
(blood, drug therapy)
- Hyperlipoproteinemia Type IV
(blood, drug therapy)
- Male
- Middle Aged
- Triglycerides
(blood)
|